Your browser is no longer supported. Please, upgrade your browser.
Settings
FATE Fate Therapeutics, Inc. daily Stock Chart
FATE [NASD]
Fate Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.07 Insider Own0.20% Shs Outstand40.25M Perf Week-3.21%
Market Cap194.41M Forward P/E- EPS next Y-0.86 Insider Trans- Shs Float40.25M Perf Month18.67%
Income-33.50M PEG- EPS next Q-0.20 Inst Own74.70% Short Float0.88% Perf Quarter73.74%
Sales4.40M P/S44.18 EPS this Y10.50% Inst Trans26.75% Short Ratio0.94 Perf Half Y40.41%
Book/sh1.96 P/B2.46 EPS next Y6.70% ROA-53.10% Target Price7.00 Perf Year161.08%
Cash/sh2.29 P/C2.11 EPS next 5Y- ROE-87.80% 52W Range1.47 - 5.68 Perf YTD92.43%
Dividend- P/FCF- EPS past 5Y-8.50% ROI-38.10% 52W High-14.96% Beta1.61
Dividend %- Quick Ratio6.10 Sales past 5Y30.30% Gross Margin- 52W Low228.57% ATR0.40
Employees60 Current Ratio6.10 Sales Q/Q-9.10% Oper. Margin- RSI (14)61.78 Volatility8.83% 8.03%
OptionableNo Debt/Eq0.15 EPS Q/Q17.80% Profit Margin- Rel Volume0.85 Prev Close4.77
ShortableYes LT Debt/Eq0.03 EarningsMar 16 AMC Payout- Avg Volume374.54K Price4.83
Recom1.70 SMA207.02% SMA5031.07% SMA20073.72% Volume318,275 Change1.26%
Nov-08-16Reiterated Wedbush Outperform $8 → $7
Sep-22-16Initiated ROTH Capital Buy $8
Jul-28-16Resumed H.C. Wainwright Buy $9
Dec-04-15Initiated Wells Fargo Outperform
Oct-06-15Initiated Raymond James Outperform $8
Jun-01-15Initiated Leerink Partners Outperform $10
May-11-15Reiterated H.C. Wainwright Buy $9 → $11
Sep-08-14Initiated H.C. Wainwright Buy $9
Oct-28-13Initiated Cowen Outperform
Mar-27-17 03:56PM  ETFs with exposure to Fate Therapeutics, Inc. : March 27, 2017
Mar-23-17 01:04PM  FATE THERAPEUTICS INC Financials +5.45%
Mar-21-17 11:31AM  Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 -9.22%
09:55AM  Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
Mar-17-17 08:33AM  A Data-Rich Year Has Analysts Accepting Their Fate Therapeutics Trade +6.68%
Mar-16-17 04:02PM  FATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:01PM  Fate Therapeutics Reports Fourth Quarter 2016 Financial Results GlobeNewswire
Mar-13-17 08:00AM  Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy GlobeNewswire +5.21%
Mar-09-17 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire +11.27%
Mar-08-17 09:30AM  Zacks.com featured highlights: Apollo Investment, Ballard Power Systems, Cymabay Therapeutics, Fate Therpautics and Oclaro
Mar-07-17 02:41PM  Explosive Stocks Under $10
Mar-02-17 04:01PM  Fate Therapeutics to Highlight Natural Killer Cell Programs and Engineered Pluripotent Cell Platform for Off-the-Shelf Cancer Immunotherapy at the 2017 AACR Annual Meeting GlobeNewswire
Mar-01-17 04:01PM  Fate Therapeutics to Present at Two Upcoming Conferences in March GlobeNewswire
Feb-27-17 08:00AM  Fate Therapeutics and Regents of the University of Minnesota Expand Research Collaboration for Clinical Translation of Engineered iPSC-Derived Natural Killer Cell Cancer Immunotherapy GlobeNewswire
Feb-22-17 08:22AM  Fate Therapeutics (FATE) Shares March Higher, Can It Continue?
Feb-20-17 07:52AM  Forget Alexion, Buy these 4 Biotech Stocks Instead
Feb-14-17 09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics +6.71%
Feb-13-17 09:14AM  Forget Gilead, Buy These 5 Biotech Stocks Instead
Feb-08-17 04:01PM  Fate Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference GlobeNewswire
Jan-20-17 04:36AM  Fate Therapeutics (FATE) Shares March Higher, Can It Continue?
Jan-05-17 08:00AM  Fate Therapeutics Announces First Patient Treated in ProTmune PROTECT Clinical Trial for the Prevention of Graft-Versus-Host Disease GlobeNewswire
Dec-12-16 11:44PM  How Zafgen Inc (ZFGN) Stacks Up Against Its Peers at Insider Monkey
Nov-29-16 06:04AM  FATE THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial
Nov-22-16 07:07PM  Fate Therapeutics Inc (FATE) Stock: Soaring On Financing And EU Approval at Insider Monkey +10.53%
02:22PM  Rotation Is the Name of the Game
08:31AM  FATE THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Sec
08:00AM  Fate Therapeutics Announces Private Financing GlobeNewswire
Nov-10-16 12:19PM  ETFs with exposure to Fate Therapeutics, Inc. : November 10, 2016
Nov-09-16 11:55AM  Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016
Nov-07-16 05:02PM  Fate Therapeutics reports 3Q loss
04:07PM  FATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:01PM  Fate Therapeutics Reports Third Quarter 2016 Financial Results GlobeNewswire
Nov-03-16 04:59PM  Fate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual Meeting GlobeNewswire -5.41%
Oct-31-16 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2016 Financial Results on November 7, 2016 GlobeNewswire
Oct-05-16 08:00AM  Fate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions GlobeNewswire
Sep-26-16 10:15AM  4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate at 24/7 Wall St.
08:00AM  Fate Therapeutics Receives FDA Orphan Drug Designation for ProTmune in Allogeneic Hematopoietic Cell Transplantation GlobeNewswire
Sep-23-16 10:36AM  Can The Uptrend Continue for Fate Therapeutics (FATE)?
Sep-22-16 08:02AM  Coverage initiated on Fate Therapeutics by ROTH Capital +11.32%
Sep-13-16 09:43AM  5 Biotech Stocks That Are Broker Favorites
Sep-09-16 10:44AM  ETFs with exposure to Fate Therapeutics, Inc. : September 9, 2016
Sep-07-16 04:03PM  FATE THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies GlobeNewswire
Aug-31-16 04:01PM  Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-29-16 11:23AM  ETFs with exposure to Fate Therapeutics, Inc. : August 29, 2016
Aug-12-16 02:21PM  ETFs with exposure to Fate Therapeutics, Inc. : August 12, 2016 +7.56%
Aug-11-16 11:13AM  Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
Aug-10-16 04:01PM  Fate Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference GlobeNewswire -7.57%
Aug-09-16 08:15AM  Fate Therapeutics (FATE) Jumps: Stock Moves 22.8% Higher
Aug-08-16 07:15PM  Fate Therapeutics reports 2Q loss +22.75%
04:03PM  FATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:01PM  Fate Therapeutics Reports Second Quarter 2016 Financial Results GlobeNewswire
08:00AM  Fate Therapeutics Announces $10.3 Million Common Stock Private Placement GlobeNewswire
Aug-02-16 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2016 Financial Results on August 8, 2016 GlobeNewswire
Aug-01-16 08:56AM  Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Jul-29-16 08:15AM  Fate Therapeutics (FATE) Catches Eye: Stock Rises 5.9%
Jul-26-16 08:01AM  Fate Therapeutics Announces Issuance of U.S. Patent on Compositions of Human Induced Pluripotent Cells GlobeNewswire
Jun-21-16 11:46AM  Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up -5.50%
08:25AM  Fate Therapeutics (FATE) Catches Eye: Stock Jumps 19.1%
Jun-20-16 11:21AM  Heres Why Traders Are Buzzing About These Five Stocks on Monday at Insider Monkey +19.05%
08:40AM  Could This Be a Turning Point for Fate Therapeutics? at 24/7 Wall St.
08:01AM  Fate Therapeutics Announces FDA Fast Track Designation for ProTmune GlobeNewswire
Jun-16-16 08:01AM  Fate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International Society for Stem Cell Research GlobeNewswire
Jun-11-16 11:01AM  Fate Therapeutics Announces Preclinical Data from Immuno-Regulatory CD34+ Cell Therapy for Autoimmune Diseases GlobeNewswire
May-17-16 08:01AM  Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer GlobeNewswire
May-16-16 08:01AM  Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy GlobeNewswire
May-12-16 05:30PM  FATE THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events -5.92%
May-09-16 05:12PM  Fate Therapeutics reports 1Q loss
04:41PM  FATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:01PM  Fate Therapeutics Reports First Quarter 2016 Financial Results GlobeNewswire
May-02-16 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016 GlobeNewswire
Apr-11-16 08:15AM  Fate Therapeutics (FATE) Jumps: Stock Moves 6.5% Higher
Apr-05-16 04:01PM  Fate Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference GlobeNewswire
Mar-04-16 07:14AM  5 Stocks Poised for Big Breakouts at TheStreet +7.65%
Mar-03-16 04:54PM  Fate Therapeutics reports 4Q loss +7.65%
04:04PM  FATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
Feb-29-16 08:15AM  Fate Therapeutics (FATE) Catches Eye: Stock Rises 8.3%
Feb-25-16 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016 GlobeNewswire +11.92%
Feb-21-16 08:01AM  Fate Therapeutics to Present Preclinical Data for ProTmune at 2016 BMT Tandem Meetings GlobeNewswire
Feb-04-16 01:40PM  Novo Nordisk Posts In Line Q4 Earnings, Tops Revenues +8.57%
Feb-03-16 04:01PM  Fate Therapeutics to Present at Leerink Partners 5th Annual Global Healthcare Conference GlobeNewswire -14.63%
Feb-01-16 08:00AM  Biotech Sector Report; Potential Rebound for These Four Biotech Securities Accesswire
Jan-27-16 02:00PM  Fate (FATE) to Move ProTmune into Phase I/II Study in Mid-16 -11.69%
10:34AM  Fate Therapeutics Gives Up Gains After Early Morning Surge
Jan-26-16 05:23PM  Total System Services, Lannett And Fate Therapeutics Moving After-Hours
04:54PM  Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection at noodls
04:36PM  Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection GlobeNewswire
Jan-14-16 04:43PM  FATE THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-07-16 04:22PM  Edited Transcript of FATE earnings conference call or presentation 3-Nov-15 10:00pm GMT -11.76%
Jan-06-16 04:01PM  Fate Therapeutics to Present at Biotech Showcase 2016 GlobeNewswire
Dec-09-15 08:40AM  Can Fate Therapeutics (FATE) Keep the Earnings Streak Alive This Quarter?
Dec-07-15 08:01AM  FATE THERAPEUTICS INC Files SEC form 8-K, Other Events -14.25%
08:00AM  Fate Therapeutics Conference Call to Provide Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation scheduled for 8:00 am ET today
06:00AM  Fate Therapeutics Provides Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation GlobeNewswire
Dec-03-15 08:01AM  Fate Therapeutics to Present at Oppenheimer & Co. 26th Annual Healthcare Conference GlobeNewswire
Dec-01-15 09:00AM  Technical Data Reveals Conditions of Growth - Research on Entegra Financial, Fate Therapeutics, Provident Bancorp, and Mirna Therapeutics Accesswire
Nov-21-15 02:48PM  Hedge Funds Own Over 25% Of Fate Therapeutics Inc (FATE) at Insider Monkey
Nov-18-15 08:30AM  Fate Therapeutics (FATE) Catches Eye: Stock Moves 5.3% Higher
Nov-05-15 09:05AM  Fate Therapeutics to Present Strategy for the Development of Off-the-Shelf Cancer Immunotherapies at ASH 2015 GlobeNewswire
09:01AM  Fate Therapeutics to Present Preclinical Data for ProTmune(TM) at ASH 2015 Annual Meeting GlobeNewswire
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular immunotherapies for cancer and immune disorders in the United States. Its novel ex vivo cell programming approach applies to modulate the therapeutic function and direct the fate of immune cells. The company's lead product candidate is ProTmune, a programmed immuno-regulatory cell therapy that is in clinical development stage for the prevention of acute graft-versus-host disease and cytomegalovirus infection in immunocompromised patients undergoing allogeneic hematopoietic cell transplantation. Its preclinical programs include NK- and T-cell cancer immunotherapies, such as off-the-shelf therapies derived from engineered induced pluripotent cells comprising iNK cell therapy and iT cell therapy; and a CD34+ cell immuno-regulatory therapy to suppress aberrant auto-reactive effector cells for autoimmune diseases. The company has a research collaboration and license agreement with Juno Therapeutics, Inc. to identify and apply small molecule modulators to enhance the therapeutic function of genetically-engineered chimeric antigen receptor T-cell and T-cell receptor immunotherapies. It has a partnership agreement with Memorial Sloan Kettering Cancer Center for the development of off-the-shelf T-cell product candidates using engineered pluripotent cell lines; and an immunotherapy collaboration with the University of Minnesota. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Storgard ChrisChief Medical OfficerNov 23Buy2.6637,59399,99737,593Nov 28 03:46 PM
RASTETTER WILLIAM HDirectorNov 23Buy2.66375,939999,998459,272Nov 28 03:44 PM
Coughlin Timothy PDirectorNov 23Buy2.6656,390149,99756,390Nov 28 03:42 PM
Wolchko J ScottPresident and CEOAug 23Option Exercise1.372,5703,521142,049Aug 24 06:55 PM